CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Indoco Remedies Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Indoco Remedies Ltd
166 Indoco House
Cst Road, Santacruz East
Phone: +91 2226541851p:+91 2226541851 MUMBAI, 400098  India Ticker: INDOCOINDOCO

Business Summary
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products for the Indian and international markets. In the international market, it has tie-ups with generic companies across the globe. It has approximately eight domestic marketing divisions, with a brand portfolio in various therapeutic segments including gastro-intestinal, respiratory, anti-infective, stomatologicals, ophthalmic, nutritionals, cardiovascular, anti-diabetics, pain management, gynecology and others. The Company's brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral and Rexidin. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20243/31/2024Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Non-Independent Chairman of the Board Suresh G.Kare 7/1/2023 6/30/2023
Chief Executive Officer, Managing Director, Executive Director Aditi K.Panandikar 54 2/15/2012 4/1/2004
Chief Financial Officer PramodGhorpade 1/1/2023 11/2/2021
6 additional Officers and Directors records available in full report.

Business Names
Business Name
532612
INDOCO

General Information
Number of Employees: 5,931 (As of 3/31/2024)
Outstanding Shares: 92,152,455 (As of 9/30/2024)
Shareholders: 33,797
Stock Exchange: NSE
Fax Number: +91 2226523980


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024